Articles

acc pharmaceuticals renal denervation heart valve repair antiplatelet therapy

Clinical trials for a promising new class of cholesterol-lowering medications, a long-awaited repair of the Medicare formula for paying physicians, the Affordable Care Act, new technology and the...

cath lab cardiac pacs radiation dose management pci embolic protection devices

Careful documentation of patient selection and procedure appropriateness are critical — yet underutilized — steps in ensuring high-quality clinical care for percutaneous coronary intervention (PCI...

stony brook JAMA cath lab clinical trial study pharmaceuticals angioplasty

For patients with stable coronary artery disease (CAD) who are not experiencing a heart attack and an abnormal stress test, treatment of their narrowed arteries by the common procedure of...

medtronic symplicity spyral renal denervation cath lab hypertension treatment G3

Medtronic Inc. announced CE mark in Europe and Therapeutic Goods Administration (TGA) listing in Australia for its flexible 4 French multi-electrode Symplicity Spyral ...

Combining genetic data with clinical information to determine the initial dosage of the blood thinner warfarin, used to prevent blood clots in the circulatory system, was no more effective in...

CORAL trial subgroups, renal stenting

The use of renal stenting in combination with medication-based therapy to treat hypertension showed no improvement in patient outcomes over the use of medications alone in treating hypertension....

The American College of Cardiology (ACC) and the American Heart Association (AHA) released a clinical practice guideline to help primary care clinicians better identify adults who may be at high...

Professional cardiovascular societies and many working cardiologists question the U.S. Food and Drug Administration’s (FDA’s) recent recommendation that patients undergo genetic testing before...

renal denervation clinical trial study hypertension cath medtronic symplicity

Medtronic Inc. announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE), allowing the company to initiate SYMPLICITY HTN-4, the first...

cath lab clinical trial study pharmaceuticals antiplatelet therapy arctic

Patients who do not experience a major cardiac event in the first year after receiving drug-eluting stent (DES) may not need to receive prolonged dual ...